Sarepta investors, analysts shrug off E.U. setback for Duchenne drug By: Boston Business Journal via Business Journals September 21, 2018 at 12:01 PM EDT European approval of the drug "is a matter of 'when' not 'if,'" according to one analyst note. Read More >>